Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03507686 · ClinicalTrials.gov registry record · Phase 2
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT03507686 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 66 participants.
The verdict
NCT03507686, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).
Interventions
- DRUG BIIB111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-11-29 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03507686
The ClinicalTrials.gov registry entry for NCT03507686 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB111 is the first listed.
NCT03507686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03507686 about?
NCT03507686 is a clinical study titled "A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111". The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).
What is the current status of trial NCT03507686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2017-11-29. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT03507686?
The interventions under investigation include: BIIB111 (DRUG).
Who is sponsoring clinical trial NCT03507686?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.